These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 15015904)

  • 1. Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate.
    Wolraich ML; Doffing MA
    CNS Drugs; 2004; 18(4):243-50. PubMed ID: 15015904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies.
    Swanson J; Gupta S; Lam A; Shoulson I; Lerner M; Modi N; Lindemulder E; Wigal S
    Arch Gen Psychiatry; 2003 Feb; 60(2):204-11. PubMed ID: 12578439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data.
    Sonuga-Barke EJ; Swanson JM; Coghill D; DeCory HH; Hatch SJ
    BMC Psychiatry; 2004 Sep; 4():28. PubMed ID: 15458569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system.
    Heal DJ; Pierce DM
    CNS Drugs; 2006; 20(9):713-38. PubMed ID: 16953648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylphenidate controlled-delivery capsules (EquasymXL, Metadate CD): a review of its use in the treatment of children and adolescents with attention-deficit hyperactivity disorder.
    Anderson VR; Keating GM
    Paediatr Drugs; 2006; 8(5):319-33. PubMed ID: 17037949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder.
    Quinn D; Wigal S; Swanson J; Hirsch S; Ottolini Y; Dariani M; Roffman M; Zeldis J; Cooper T
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1422-9. PubMed ID: 15502602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
    Pliszka SR; Wilens TE; Bostrom S; Arnold VK; Marraffino A; Cutler AJ; López FA; DeSousa NJ; Sallee FR; Incledon B; Newcorn JH
    J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):474-482. PubMed ID: 29172680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD.
    Childress AC; Sallee FR; Berry SA
    Postgrad Med; 2011 Sep; 123(5):80-8. PubMed ID: 21904089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and clinical effectiveness of methylphenidate.
    Kimko HC; Cross JT; Abernethy DR
    Clin Pharmacokinet; 1999 Dec; 37(6):457-70. PubMed ID: 10628897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of new compounds available in Australia for the treatment of attention-deficit hyperactivity disorder.
    Hazell P
    Australas Psychiatry; 2004 Dec; 12(4):369-75. PubMed ID: 15715810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does chirality matter? pharmacodynamics of enantiomers of methylphenidate in patients with attention-deficit/hyperactivity disorder.
    Quinn D
    J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S62-6. PubMed ID: 18480679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylphenidate transdermal system: In attention-deficit hyperactivity disorder in children.
    Anderson VR; Scott LJ
    Drugs; 2006; 66(8):1117-26. PubMed ID: 16789796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-release methylphenidate (Ritalin LA).
    Lyseng-Williamson KA; Keating GM
    Drugs; 2002; 62(15):2251-9; discussion 2260-1. PubMed ID: 12381228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained-release methylphenidate: new preparations. New pharmaceutical forms: a slight advantage for a small number of children.
    Prescrire Int; 2004 Dec; 13(74):203-6. PubMed ID: 15612099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.
    Markowitz JS; Straughn AB; Patrick KS; DeVane CL; Pestreich L; Lee J; Wang Y; Muniz R
    Clin Pharmacokinet; 2003; 42(4):393-401. PubMed ID: 12648029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of modified-release methylphenidate in the treatment of attention-deficit/hyperactivity disorder.
    Childress A; Belchenko D; Lempa B
    Expert Rev Neurother; 2017 Feb; 17(2):113-121. PubMed ID: 27936986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Formulations of Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder: Pharmacokinetics, Efficacy, and Tolerability.
    Cortese S; D'Acunto G; Konofal E; Masi G; Vitiello B
    CNS Drugs; 2017 Feb; 31(2):149-160. PubMed ID: 28130762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate.
    Maldonado R
    Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1001-14. PubMed ID: 23611637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.